Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term follow-up study of intradetrusor BOTOX for neurogenic detrusor overactivity-related urinary incontinence
NL-OMON37968Phase 3Active, not recruiting
- Sponsor
- Allergan
- Start
- Oct 2009
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of botulinum toxin type A in detrusor hyperreflexia (DH), urinary incontinence (UI) and overactive bladder (OAB), sponsored by Allergan. Primary endpoint: Change from baseline in daily average urinary incontinence episodes. Started Oct 2009; status: active, not recruiting.
02
Drugs
botulinum toxin type A
03
Conditions
detrusor hyperreflexia (DH)urinary incontinence (UI)overactive bladder (OAB)
Beyond the preview
Go deeper on NL-OMON37968.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON37968.